Fritze D, Kern D H, Pilch Y H
Klin Wochenschr. 1976 Sep 15;54(18):851-63. doi: 10.1007/BF01483586.
Ribonucleic acids extracted from specifically sensitized lymphoid cells (I-RNA) have been shown to transfer specific immunoreactivity to normal non-immune lymphoid cells. Evidence for the transfer by I-RNA, of immune responses to tumor-associated antigens of animal and human neoplasms, in vivo and in vitro, is reviewed. Results obtained in our laboratory and in other laboratories indicate that xenogeneic, allogeneic and syngeneic I-RNA extracts mediate specific cytotoxicity to tumor cells, in vitro, and mediate transplantation resistance and tumor rejection responses in vivo. Our results suggest that I-RNA preparations fail to elicit immune responses directed against "self" antigens. By contrast, I-RNA's directed against "non-self" tumor-associated antigens appear to induce lymphocytes to effect specific anti-tumor immune responses. The mechanisms responsible for the failure of I-RNA to initiate immune responses against "self" antigens are not known at present and demand investigation. Preliminary results of a clinical Phase I trial of immunotherapy with xenogeneic I-RNA in selected cancer patients are reviewed. I-RNA might offer promise as a new modality for the immunotherapy of human cancer.
从特异性致敏淋巴细胞中提取的核糖核酸（I-RNA）已被证明能将特异性免疫反应传递给正常的非免疫淋巴细胞。本文综述了I-RNA在体内和体外对动物及人类肿瘤的肿瘤相关抗原的免疫反应传递的证据。我们实验室和其他实验室获得的结果表明，异种、同种异体和同基因I-RNA提取物在体外介导对肿瘤细胞的特异性细胞毒性，并在体内介导移植抗性和肿瘤排斥反应。我们的结果表明，I-RNA制剂未能引发针对“自身”抗原的免疫反应。相比之下，针对“非自身”肿瘤相关抗原的I-RNA似乎能诱导淋巴细胞产生特异性抗肿瘤免疫反应。目前尚不清楚I-RNA未能引发针对“自身”抗原的免疫反应的机制，需要进行研究。本文综述了在选定癌症患者中进行异种I-RNA免疫治疗的临床I期试验的初步结果。I-RNA有望成为人类癌症免疫治疗的一种新方法。
